Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults
Sponsor: GC Biopharma Corp
Summary
A Phase 1, Randomized, Double-blind, Dose-Escalation, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Preventive Vaccine 'GC4006A' in Healthy Adults Aged 19 to 64 Years
Official title: A Phase 1, Randomized, Double-blind, Dose-Escalation, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Preventive Vaccine 'GC4006A' in Healthy Adults Aged 19 to 64 Years
Key Details
Gender
All
Age Range
19 Years - 64 Years
Study Type
INTERVENTIONAL
Enrollment
72
Start Date
2026-01-28
Completion Date
2027-05
Last Updated
2026-07-27
Healthy Volunteers
Yes
Conditions
Interventions
GC4006A
administered as a single dose via Intramuscular injection.
Normal Saline
Matching placebo administered as a single dose via Intramuscular injection.
Locations (1)
Korea University Guro Hospital
Seoul, South Korea